What Is CJC-1295 and Why Australian Researchers Are Studying It
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) — a 30-amino-acid peptide engineered to mimic the body's own GHRH-(1-29) sequence while resisting the rapid enzymatic degradation that limits the natural hormone. With around 1,000 monthly searches in Australia for the hyphenated form and another 2,900 for "cjc 1295" alone, it sits firmly inside the most-researched cohort of growth hormone peptides in the country. The compound was developed at ConjuChem in the early 2000s, with the original goal of producing a stable GHRH analogue suitable for pharmaceutical research.
Two distinct molecules circulate under the "CJC-1295" name. CJC-1295 with DAC (Drug Affinity Complex) carries a maleimide-containing linker that covalently binds to serum albumin, extending its half-life dramatically. CJC-1295 without DAC — sometimes called Modified GRF (1-29) — lacks the albumin-binding tail and has a much shorter window of activity. Australian researchers most often pair the no-DAC version with CJC-1295 + Ipamorelin blends for studies of pulsatile growth hormone release, because the shorter window better preserves the body's natural GH pulse architecture.
Mechanism of Action: How CJC-1295 Engages the Pituitary
CJC-1295 binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary. Engagement of this G-protein-coupled receptor activates adenylyl cyclase, raises intracellular cyclic AMP, and triggers the release of stored growth hormone vesicles. Crucially, the compound does not synthesise growth hormone artificially — it amplifies the pituitary's own production capacity by sensitising and stimulating the somatotrophs the body already has. Once GH is released, it travels to the liver and other tissues to drive insulin-like growth factor 1 (IGF-1) production, which mediates many of growth hormone's downstream effects on tissue repair, protein synthesis, and substrate metabolism.
The DAC modification is the engineering centrepiece. By tethering the peptide to serum albumin via a stable thioether bond, the half-life extends from minutes (native GHRH) to roughly 6–8 days in animal pharmacokinetic studies. Researchers studying chronic GHRH receptor engagement use the DAC version; researchers wanting to model physiological GH pulsatility — which is widely thought to be biologically important — use the no-DAC version. This pulsatility distinction matters: continuous GHRH receptor engagement may produce different downstream effects than intermittent stimulation, and animal models suggest the no-DAC pulsatile pattern more closely resembles endogenous GH secretion.
One nuance often missed in introductory material: GH release is not governed by GHRH alone. Somatostatin, released from the hypothalamus on its own rhythm, actively suppresses pituitary GH secretion. The pulsatile pattern of endogenous GH that researchers observe in healthy animals reflects the interplay of these two opposing signals — GHRH driving release, somatostatin gating it. CJC-1295 acts on only one side of that equation, which is why the literature consistently shows it amplifies natural GH peaks rather than producing tonic, somatostatin-resistant elevation. Understanding this dual-control architecture is essential for interpreting any data generated with GHRH analogues.
The CJC-1295 + Ipamorelin Combination in Research
The most-studied protocol in the literature pairs CJC-1295 (no DAC) with Ipamorelin, a selective ghrelin receptor agonist. The two compounds work through complementary pathways: CJC-1295 stimulates GHRH receptors while Ipamorelin engages the growth hormone secretagogue receptor (GHSR-1a). Activating both receptor systems simultaneously produces a synergistic effect — preclinical studies show GH release exceeding what either compound generates individually, with no measurable elevation in cortisol, prolactin, or aldosterone.
This receptor selectivity is one reason the combination is so prevalent in research settings. Earlier-generation growth hormone secretagogues like GHRP-6 and Hexarelin also activated cortisol and prolactin pathways, complicating interpretation of metabolic data. Ipamorelin's selectivity for GHSR-1a avoids those off-target effects, while CJC-1295 contributes the GHRH-receptor-mediated component. Together they engage both arms of the dual-pathway model of GH regulation that emerged from research in the 1990s and 2000s.
Pharmacokinetics, Half-Life and Stability Considerations
CJC-1295 with DAC has, as noted, an extended half-life of approximately 6–8 days in published animal models, with measurable GH and IGF-1 elevations sustained for over a week after a single administration. The no-DAC form (Modified GRF 1-29) has a half-life of roughly 30 minutes, which is why research protocols using the no-DAC version typically involve more frequent administration to maintain receptor engagement. This pharmacokinetic difference drives almost every protocol decision in the literature: dose, frequency, and combination choice all hinge on which form is being used.
Stability is another factor researchers must account for. Lyophilised CJC-1295 powder is stable at room temperature for several months when protected from light and moisture, with longer storage typically at -20°C. Once reconstituted with bacteriostatic water, the peptide should be refrigerated at 2–8°C and used within approximately 28 days, consistent with the broader peptide research literature on reconstituted-peptide stability. Peptide storage protocols matter — improper handling degrades the compound and confounds research outcomes.
Reconstitution accuracy also affects every downstream measurement. The same vial reconstituted with 1 ml versus 2 ml of bacteriostatic water yields a two-fold concentration difference, and unintentional concentration drift propagates through every dose-response curve drawn from that material. Research-grade work requires deliberate, documented reconstitution ratios and consistent application of those ratios across replicates. Reconstitution calculation tools help reduce arithmetic errors that would otherwise contaminate the data.
Australian Regulatory Context for CJC-1295 Research
CJC-1295 is not currently scheduled under the Australian Poisons Standard, meaning it is not a controlled substance under the SUSMP. However, like all research peptides supplied in Australia, it is not an approved therapeutic good — it has not been entered onto the Australian Register of Therapeutic Goods (ARTG) and cannot legally be sold or marketed for human therapeutic use. Optic Labs supplies CJC-1295 + Ipamorelin blends strictly for research purposes, with independent HPLC and mass spectrometry verification of identity and purity for every batch. The Australian regulatory framework places clear obligations on suppliers and researchers alike.
Researchers working with CJC-1295 in institutional settings should confirm that their work is covered by appropriate ethics committee approvals and institutional research policies. Domestic Australian sourcing — rather than overseas importation — provides the cleanest path to compliant research-grade material with verifiable provenance, intact cold chain, and a Certificate of Analysis tied to a specific batch.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), engineered to be more stable than the native peptide. Two forms exist: CJC-1295 with DAC (long-acting, ~6–8 day half-life via albumin binding) and CJC-1295 without DAC, also called Modified GRF (1-29), which has a roughly 30-minute half-life. Both bind the pituitary GHRH receptor to stimulate growth hormone release in research models.
What does CJC-1295 do in research models?
In animal and cell-culture studies, CJC-1295 stimulates the pituitary's somatotroph cells to release growth hormone, which in turn drives liver IGF-1 production. Research has examined its effects on protein synthesis pathways, tissue repair signalling, and metabolic substrate handling. The compound does not produce growth hormone synthetically — it amplifies the body's own GH-producing capacity in the models studied.
How does CJC-1295 differ from Ipamorelin?
The two compounds engage different receptors. CJC-1295 binds the GHRH receptor (GHRHR) on pituitary somatotrophs. Ipamorelin binds the growth hormone secretagogue receptor (GHSR-1a), the same receptor activated by ghrelin. Because they act through complementary pathways, research protocols often combine them to produce a synergistic effect on GH release — exceeding what either compound achieves alone in published animal data.
Is CJC-1295 legal in Australia for research?
CJC-1295 is not currently a scheduled substance under the Australian Poisons Standard, so it is not a controlled drug. However, it is not an approved therapeutic good and cannot be legally sold or marketed for human therapeutic use. It can be supplied to researchers for laboratory and research purposes only, with appropriate research-use-only labelling, certificates of analysis, and no therapeutic claims. Domestic Australian sourcing avoids the importation complexity that arises with overseas suppliers.
This article is for educational and research purposes only. Optic Labs products are intended for research use only and are not for human consumption. Always consult a qualified healthcare professional before considering any compounds.